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Abstract 
 
A potential strategy to alleviate the aggregation of intrinsically disordered proteins 
(IDPs) is to maintain the native functional state of the protein by small molecule binding. 
However, the targeting of the native state of IDPs by small molecules has been challenging 
due to their heterogeneous conformational ensembles. To tackle this challenge, we applied a 
high-throughput chemical microarray surface plasmon resonance imaging screen to detect the 
binding between small molecules and monomeric full-length Tau, a protein linked with the 
onset of a range of Tauopathies. The screen identified a novel set of drug-like fragment and 
lead-like compounds that bound to Tau. We verified that the majority of these hit compounds 
reduced the aggregation of different Tau constructs in vitro and in N2a cells. These results 
demonstrate that Tau is a viable receptor of drug-like small molecules. The drug discovery 
approach that we present can be applied to other IDPs linked to other misfolding diseases 
such as Alzheimer’s and Parkinson’s diseases. 
 
 
 
 
Keywords: Alzheimer’s Disease, drug discovery, high throughput screening, inhibitor, 
protein aggregation, Tau, Taupathies, thearapeutic  
Introduction 
 
Tauopathies [1] represent a subset of neurodegenerative disorders, including 
Alzheimer’s disease (AD) [2] and frontotemporal dementias (FTD) [1], which are linked to 
the accumulation of aberrant protein deposits known as neurofibrillary tangles (NFTs), which 
are formed by microtubule-associated protein Tau (MAPT) in patients’ brains. NFTs consist 
of paired helical filaments (PHFs) of Tau generated by the aggregation of monomeric Tau in 
neurons. Tau is an intrinsically disordered protein (IDP) with six main isoforms in the human 
CNS [3], the longest of which is of 441 residues. While no Tau mutations have been linked 
yet to the early onset of AD, familial mutations in the Tau gene on chromosome 17 (FTDP-
17) have been identified that cause early-onset forms of FTD with Parkinsonism [4]. Under 
normal conditions Tau is known to stabilize microtubules within cells. In AD, however, Tau 
is hyperphosphorylated, which reduces its affinity towards microtubules [5]. This lack of 
binding to microtubules could be one of the reasons why Tau aggregates abnormally, initially 
in small oligomers and later in PHFs [6].  
A potential strategy to alleviate the aggregation of proteins and their consequent 
toxicity linked to disease is to use small molecules to inhibit the aggregation process itself. 
This approach has been pursued for Tau [7-11] by applying high-throughput screens to detect 
the formation of protein fibrils. Some of these screening efforts resulted in Tau aggregation 
inhibitors, which have been shown to be neuroprotective [12-15]. However, a majority of hit 
compounds derived from such screens have been shown to inhibit fibril formation through 
nonspecific or reactive mechanisms [11; 12; 16; 17], a situation that impedes the application 
of traditional medicinal chemistry approaches to further optimize these compounds. Because 
NFT deposits have been reported to be less toxic compared to their oligomeric precursors [18-
21], the detection and elimination of small oligomeric species should be the principal goal of 
new screening efforts [22]. 
To reduce potential toxic oligomer and fibril formation, a possible approach is to 
target the early phases of the aggregation process. This goal may be accomplished through 
small molecules that bind to the monomeric proteins and thereby reduce their misfolding and 
aggregation through stabilizing and promoting the functional native states of the proteins. 
This type of approach has been successful in the development of a small-molecule therapeutic 
for the globular folded protein transthyretin [23], whose misfolding is linked to systemic 
amyloidosis and related disorders [24]. This strategy could also work for inhibiting Tau 
aggregation, for instance because compounds could bind to and stabilize a specific 
conformational state of the monomeric ensemble of Tau, known as the paperclip 
conformation [25], a preferred global folding of Tau which brings the N-terminal and C-
terminal domains into the vicinity of the repeat domain, and thus protects against pathological 
aggregation. The stabilization of the monomeric form by small molecules should reduce the 
rates of all the monomer-dependent processes during aggregation [26]. Therefore, delaying or 
stopping the initial steps of oligomer formation this way should lead to the reduction or 
elimination of toxic Tau oligomers. Such a therapeutic approach should be able to slow down 
the progression of Tauophathies and could also prove to be preventive. However, the 
structural heterogeneity of the conformational ensemble of Tau and other IDPs presents a 
major challenge [27]. The feasibility of binding of drug-like small molecules specifically to 
the monomeric forms of Tau and other IDPs has not yet been definitively established. 
In this study, we pursue an alternative approach to those reported previously for 
identifying small molecule inhibitors of Tau [7-11]. First, we apply a high-throughput 
chemical microarray surface plasmon resonance imaging screen (HT-CM-SPR) [28; 34-36], 
which has the ability to detect the interaction between immobilized small molecules and 
monomeric full length Tau (hTau2N4Rwt), to probe whether the binding of fragments and/or 
lead-like compounds to Tau is feasible. In contrast to more common SPR approaches, in 
which the protein target itself is immobilized on the sensor surface, this “reverse SPR” 
scheme exploits the advantages of having large collections of compounds immobilized on 
chemical microarrays (Fig. 1). Because the surface chemistry applied for the chemical 
microarray allows controlling the orientation and density of the compounds precisely, the 
technique is applicable to the screening of a variety of biomolecules (including structured and 
intrinsically disorder proteins, and antibodies) with a variety of structures. This universal 
screening platform has been a powerful tool for the identification of small molecule binders to 
proteins providing valuable starting points for hit-to-lead optimization in various drug 
discovery projects [28; 34-36].  Next, we identified novel small molecule binders capable of 
modulating Tau aggregation in vitro and in N2a cells. Our overall goal is to identify drug-like 
small molecules that bind to monomeric Tau and can reduce its aggregation. By specifically 
targeting the monomeric state of Tau, we anticipate that it will be possible to identify small 
molecules that modulate Tau aggregation at the earliest phases of its fibrillization pathway. 
 
 
 
 
 
Materials and Methods 
 
Expression and purification of hTau2N4Rwt, Tau3RD and Tau4RDΔK280 
The human Tau constructs were expressed in pNG2 vector, a derivative of pET-3a 
(Merck-Novagen, Darmstadt) in E.coli strain BL21(DE3) (Merck-Novagen, Darmstadt). The 
expressed protein was purified from bacterial extract by making use of the heat stability of 
Tau protein. The cell pellet was resuspended in the boiling-extraction buffer (50 mM MES, 
500 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 5 mM DTT, pH 6.8) complemented with 
protease inhibitor coctail (1 mM PMSF, 1 mM EDTA, 1 mM EGTA, 1 mM benzamidin, 1 
µg/ml leupeptin, 1 µg/mL aprotinin, and 1 µg/ml pepstatin). The cells were disrupted with a 
French pressure cell and subsequently boiled for 20 min. The soluble extract was isolated by 
centrifugation, the supernatant was dialyzed against the cation exchange chromatography 
buffer A (20 mM MES, 50 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM 
PMSF, pH 6.8) and loaded on cation exchange SP-Sepharose column (GE Healthcare). The 
protein was eluted by a linear gradient of cation exchange chromatography buffer B (20 mM 
MES, 1 M NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8). The short 
Tau constructs representing Tau repeat domains Tau3RD (3 repeats; (M)Q244-S372 lacking 
V275-S305 => 99 residues) or Tau4RDDK280 (4 repeats; (M)Q244-E372 lacking K on 
position 280 => 129 residues) were subsequently concentrated and rebuffered on Amicon 
Ultra-15 device (Millipore, Bedford, MA).  
The full length Tau isoform (hTau2N4Rwt) was in the first step similar purified on 
cation exchange SP-Sepharose column and in the next step the protein was loaded on size 
exclusion column Superdex G200 (GE Healthcare) and eluted with PBS Buffer (pH 7.4; 
1 mM DTT), to remove Tau breakdown products. 
Protein concentration was determined by the Bradford assay. The purity of the 
proteins was analyzed by SDS-PAGE (10% or 17%) and the monomeric state of hTau2N4Rwt 
was assessed by analysis of gel filtration column G200 fractions on SDS PAGE in non-
reducing conditions. 
 
Chemical Microarrays 
The construction of such arrays and their use for primary screening in drug discovery 
was already described elsewhere [28; 29]. Briefly, chemical microarrays with footprints of 8.2 
x 12.4 cm comprise 9,216 sensor fields each and were constructed by photolithographic 
methods. Microstructuring of glass plates and metal deposition techniques allowed generating 
arrays of sensor fields with diameters of 400µm covered with a thin gold film of defined 
thickness. The latter enables the optical read-out of the chips by SPR imaging and also 
facilitated a chip surface modification based on binary self-assembled monolayers (SAM) 
exhibiting maleimide moieties (anchors) at a controlled density. All 110,000 library 
compounds, the synthesis and QC of which was described before [30], were coupled to a 
flexible, long, hydrophilic thiol-linker, called “chemtag”, the structure of which was defined 
previously [30]. Upon pintool spotting, the linker-compounds constructs were allowed to react 
covalently with the maleimide moieties on the array surface to yield a surface architecture 
comprising the glass/gold/SAM surface/covalently attached chemtag and the immobilized 
ligands. The surface architecture resulting from coupling the chemtag-compounds conjugate 
to the chemically modified chips surface was also described previously elsewhere [28; 29]. 
The optimized surface chemistry was designed to be resistant to unspecific protein binding 
exhibiting only marginal background in the SPR screening experiments.  
 
SPR Imaging of Chemical Microarrays 
The microarrays were read out by SPR using Graffinity’s in-house developed SPR 
Imager®. The optical set-up in the instrument allowed illuminating the entire chip area with 
parallel light of defined incidence angle and wavelength via a high refractive index prism in a 
Kretschmann configuration. Reflection images of the chip were recorded by means of a 
cooled, low-noise CCD camera. While keeping the incidence angle of the incoming beam 
fixed, the wavelength was varied over a certain range covering the SPR resonance conditions 
for the given chip/prism combination. Recorded array images (close up in Fig. 1C) were 
deconvoluted by automatic spot finding routines and grey scale analysis. Plotting the 
reflectivity of the individual sensor areas versus the applied wavelength yielded 9,216 SPR 
minima (Fig. 1D) resulting from the excitation of surface plasmons. Binding of analytes (e.g. 
folded or unfolded proteins) to the immobilized library compounds altered the optical 
resonance conditions for the corresponding sensor fields. Such differences to analyte-free 
buffer were picked up by monitoring (red) shifts of the wavelength dependent SPR minima 
with time. Additionally, bulk refractive index changes upon buffer exchange were taken into 
account by control spots distributed across the array. Typical incubation times of analytes on 
the arrays ranged from 15 minutes to 3 hours during which scans were recorded repeatedly. 
SPR shifts were plotted in color coded plots (Fig. 1D). Software routines guided the hit 
selection process on the array level by fitting Gauss-like functions to the SPR signal 
distribution and suggesting hit thresholds per array allowing to remove non-hits. A great deal 
of knowledge about the interaction of library components tethered on the chip with other 
proteins is has been gathered from prior screens. Therefore, compounds showing promiscuous 
interactions (frequent binders identified to have hit > 50% of screened targets) were excluded 
from initial hits to extract compounds with possibly higher target specificity.  
 
SPR Screening of hTau2N4Rwt  
For the screening set-up, the binding behavior of the intrinsically disorder protein 
hTau2N4Rwt was evaluated on a set of 96 control ligands of defined physicochemical 
properties in order to optimize parameters such as buffer composition, surface density of 
ligands and protein concentration. A minimum of unspecific binding, low background and 
acceptable signal/noise ratio was obtained at a final screening concentration of 400 nM 
hTau2N4Rwt in 50 mM Hepes at pH 7.4, with 50 mM NaCl, 1 mM DTT and 0.01% Tween. 
 
Measurement of absorption spectra of hit compounds 
To examine possible optical interference by the compounds with the fluorescence of 
ThS absorption scans were performed. 200 µM compound in PBS-buffer plus 2% DMSO 
were scanned in a 384 well plate (flat bottom transparent, Greiner, Frickenhausen) in the 
range of 230 to 1000 nm using a Safire spectrometer (Tecan, Männerdorf, Switzerland). For 
three selected compounds the results are shown in Fig. 7A. 
 
Thioflavin-S in vitro assays of Tau aggregation and inhibition: 
ThS-based assays of Tau-aggregation [9; 31; 32] were also performed in different 
buffer systems in order to optimize aggregation properties [33] of hTau2N4Rwt (50 µM) or 
Tau4RDΔK280 (10 µM) in 20 mM BES-buffer (pH 7.4, 25 mM NaCl) plus heparin3000 (12.5 
µM) – in case of Tau4RDDK280 without heparin – and DTT (1 mM) were heated up at 98 °C 
for 20 min. After cooling down to room temperature a protease-inhibitor-mix (1 mM 
benzamidin, 1 µg/ml leupeptin, 1 µg/mL aprotinin, and 1 µg/ml pepstatin) and the compound 
to be tested (300 µM for hTau2N4Rwt, 50 µM in case of Tau4RDΔK280; molar ratio of 
compound to protein = 6:1 for hTau2N4Rwt and 5:1 for Tau4RDΔK280) were added and the 
sample was incubated for 10 days at 37°C, with addition of 1 mM DTT every day. The 
samples contained DMSO at a final concentration of 2% resulting from the solubilization of 
the compounds. Before testing the sample was diluted to 10 µM Tau concentration in PBS 
buffer, and 20 µM ThS was added (molar ratio of protein to ThS = 1:2) and incubated for 30 
min at room temperature. The measurement was performed at excitation and emission 
wavelengths of 440 nm and 521 nm, respectively. 
Construct Tau3RD (3R repeat domain of Tau, 10 µM) incubated in 50 mM NaAc (pH 
6.8) plus heparin3000 (2.5 µM) and 60 µM compound (molar ratio of compound to protein = 
6:1) were mixed and the sample incubated over night (16 h) at 37 °C. Before testing 20 µM of 
Thioflavin-S was added to the sample (ratio of protein to ThS = 1:2) and incubated for 30 min 
at room temperature. The measurement was performed at excitation wavelength of 440 nm 
and emission wavelength of 521 nm. 
For three selected compounds the results are shown in Fig. 3A and Table 4. 
 
Test of displacement of ThS from Tau fibrils by compounds: 
10 µM Tau3RD in 50 mM NH4Ac with 2.5 µM heparin3000 was incubated for 3 days at 
37°C. After incubation the Tau aggregates were stained with (a) 20 µM ThS plus 20 µM 
compound, (b) 20 µM ThS plus 200 µM compound, or (c) 200 µM compound alone. After 
incubation for 1h at room temperature the fluorescence was measured at 440 nm/521 nm 
(ex/em). For three selected compounds the results are shown in Fig. 7B and Table 4. 
 
Inhibition of Tau aggregation in N2a cells measured by FACS 
Cell suspensions of inducible N2aTau4RDΔK280 cells were distributed on 24-well 
pates (1 ml per well) and 0.0005% (12 µM) Thioflavin-S was added to each sample. For 
induction of Tau expression 1 µg/ml doxycyclin was added, except for the uninduced negative 
control. 60 µM compounds were added, except for the untreated positive control (all 
compounds were tested at 60 µM concentration). An additional assay was performed with 
some selected compounds in the concentration range of 0 to 60 µM (Fig. 6B-D; Table 4). The 
cells were incubated for 4 days at 37 °C. Floating and adherent cells were combined, pelleted 
(5 min, 295 g) and washed once with PBS. Cells were then counted in a BD FACSCantoTMII 
Flow Cytometry System by the fluorescent signal intensity in the FITC channel (Excitation: 
495 nm, Emission: 519 nm). 
 
Cell viability in the presence of compounds 
The cell viability of N2a cells in the presence of compounds was monitored by an 
MTT-assay. Uninduced N2a cells were incubated in the presence of 60 µM compound (all 
compounds) or at several compound concentrations (0 to 60 µM; Fig. 6B-D; Table 4) in the 
cell culture medium over 4 days at 37°C. The MTT-assay was performed according to the 
manufacturer's instructions (Roche, Cell Proliferation Kit, Cat.No. 11465007001).  
 
Dynamic Light Scattering (DLS) analyzes of synthesized hits 
Representative size distributions of the 70 synthesized hits in DMSO, PBS and 1 mM 
DTT at pH 7.4 at 300 mM, 150 mM, 75 mM, 37.5 mM, 18.75 mM and 9.375 mM 
concentrations were recorded at 25 ºC on DynaPro Plate reader (Wyatt) and analyzed using 
Dynamics software from the same vendor from 300 µM in 0.5% DMSO. Buffers and samples 
were filtered using a 22 micron filter prior to analyses. A 45 µl sample of the compound 
solution was added to the well of a 384 well plate (in duplicate). 
 
Resynthesis of Library Compounds 
In general synthesis of compounds for biochemical testing was done using a linker 
replacement strategy described in Neumann et al. [28]. In all cases, the linker present in the 
original screening hits was replaced by a methyl group.  
 
 
  
Results 
 
Identification of small molecule binders of full length Tau (hTau2N4Rwt) by HT-CM-SPR 
Monomeric hTau2N4Rwt (Fig. S1) was screened against an in-house library of small 
molecules at Graffinity Pharmaceuticals (Graffinity library at the time of screening: 110,000 
drug-like compounds, which include 23,000 fragment-like compounds with a molecular 
weight (MW) less than 300Da) immobilized on microarrays using HT-CM-SPR. 
To identify optimal screening conditions for HT-CM-SPR of full-length Tau 
(hTau2N4Rwt), the binding behavior of hTau2N4Rwt to a set of 96 immobilized control 
compounds (reference array) with diverse physicochemical and pharmacological properties 
(frequent binders, target class specific binders, positive and negative controls) was evaluated 
with various buffer compositions, surface densities of compounds and protein concentrations. 
Overall, these experiments resulted in identifying a screening buffer containing 50 mM Hepes 
at pH 7.4, 50 mM NaCl, 1 mM DTT, 0.01% Tween, and the use of an optimized surface 
density of immobilized ligands. Screening was done at room temperature by incubating the 
chemical microarrays with 400 nM hTau2N4Rwt for 3 hours. To probe if hTau2N4Rwt had a 
tendency to aggregate over time under the screening conditions applied, hTau2N4Rwt samples 
were incubated for 3 hours in the screening buffer and samples from it were taken in every 
hour. Potentially formed pellets from these samples were resuspended and analyzed using 
SDS PAGE. Precipitation was not observed and monomeric hTau2N4Rwt was detected 
throughout the time course of a typical array experiment of 3 hours. By using the final 
screening conditions minimal nonspecific binding to hTau2N4Rwt, a low background and 
acceptable signal/noise ratio were observed. All these observations suggest that the detected 
SPR signal in the screen reflects the interactions between monomeric hTau2N4Rwt and 
immobilized compounds. 
Monomeric hTau2N4Rwt was screened against the Graffinity library using the in-house 
developed Graffinity SPR Imagers, which allowed recording the SPR minima of four 
chemical arrays in parallel with 9,216 sensor fields each. For manual analysis of the array 
data, SPR signals were visualized in coloured two-dimensional fingerprints with the colour 
representing the intensity of SPR shift upon incubation with protein. To demonstrate this 
process, Fig. 2 shows representative examples of hTau2N4Rwt SPR fingerprints in an array 
view. For fragment libraries compounds were spotted in triplicates, hence hits for the 
fragment library appear as triplicate spots on a diagonal (Fig. 2A). In the case of lead-like 
libraries derived from combinatorial synthesis approaches, each row and column consists of a 
common molecular moiety in combination with 96 other diverse analouges (Fig. 2B), thus hit 
series identified for hTau2N4Rwt appear as line pattern (Fig. 2B). The plots on the right in 
figure 2A and B compare the SPR signals of two independent repetition experiments 
(different operator, reader, date, same hTau2N4Rwt batch). Multiplicate SPR signals were 
averaged for each immobilized array compound (e.g. fragments signals: 2 experiments x 3 
spots = hexaplicate signals). A filtering step removed potential hits for which the standard 
deviation of the SPR signal was higher than 0.8 nm (see Fig. 1C). The threshold for selection 
of Tau-binding compounds was defined as the SPR minimum that was separated from the 
background noise by at least 1 nm and for which the reproducibility criteria was satisfied. In 
addition, immobilized compounds that had low purity before spotting to the surface of the 
array and had low saturation per spot (< 80%) were disregarded. 
Generally, the overall data quality, signal strength and hit rate were lower compared to 
previously screened globular proteins. For previous screens of globular proteins of similar 
molecular weight compared to hTau2N4Rwt, hit signals were clearly separated from the 
background and signal to noise ratios of > 10 were regularly obtained, while for hTau2N4Rwt 
the array signals were rather small with S/N ratios ranging between 1.5-2.0. 
Analysis of the screening results by computational methods and by visual inspection 
of the array data identified 834 immobilized compounds as hits, which conveys a hit rate of 
approximately 0.76% for the screen. Hits were distributed over various compound classes and 
a large number of structurally independent singletons were also identified. Out of this initial 
set of 834 screening hits, we selected 118 representative hits based on parameters such as 
physicochemical properties, molecular weight, SPR signal strength, structural diversity, 
chemical tractability and overall drug-like attractiveness. None of these hit compounds have 
been reported previously to bind to Tau or affect the aggregation of the protein. These hits 
were arranged into ten different molecular scaffold classes based on their common 
substructures and prevalent physicochemical features using cheminformatic analyses. 41 
structurally unrelated lead-like and 26 fragment hits were also identified (Table 1). The 
different molecular scaffold classes had a high degree of structural diversity with a high 
number of negatively charged compounds. The ranges of some molecular properties (such as 
MW, clogP, H-bond donors and acceptors, ring count) for the above mentioned 118 
representative array-linked hits are summarized in Tables 2 and 3. 
SPR signal intensities were categorized into weak, medium and strong, which reflect 
the relative binding affinities of the immobilized compounds to the protein. Overall, most hits 
were detected to bind weakly to the protein (approximately Kd > 100 µM), with only 19 hits 
binding with medium affinity (approximately Kd < 100 µM). Many of the hits that bound with 
medium affinity were charged, 7 of the hits have a total net charge of -1 while 4 have a total 
net charge of +1. 
Hits were selected for synthesis on the basis of their binding ability to hTau2N4Rwt and 
on the basis of covering the full chemical space of the identified hits from the screen. 70 hits 
were synthesized devoid of the chemtag linker moiety, which was used to tether the 
compound to the SPR chip and replaced with appropriate atoms/groups such as methyl 
groups. The properties of these selected compounds can also be found in Table 3. 
	  
Tau binding compounds can affect the aggregation of Tau in vitro 
Our next interest was to elucidate whether the variety of small molecules, which we 
identified to bind to hTau2N4Rwt, could modulate its aggregation. To explore whether the 
synthesized hits can influence the aggregation propensity of Tau in vitro, we ran hTau2N4Rwt, 
Tau3RD (three-repeat-domain; see Materials and Methods) (with heparin), and Tau4RDΔK280 
(four-repeat-domain construct with pro-aggregant deletion of K280 [37]; see Materials and 
Methods) (without heparin) aggregation assays in the presence of hit compounds (molar ratio 
of protein to compound 1:6 for hTau2N4Rwt, Tau3RD and 1:5 for Tau4RDΔK280) using 
Thioflavin S (ThS) to detect fibril formation of the proteins. 
A number of the synthesized hits were able to inhibit fibril formation of Tau4RDΔK280 
(example illustrated by electron microscopy in Figure S2), Tau3RD and hTau2N4Rwt. In the 
case of hTau2N4Rwt aggregation assays, only about 15% of the synthesized hits had some 
inhibitory effect on the aggregation of hTau2N4Rwt (reduction of aggregation by ~10-14% 
compared to control), while control compound bb14 inhibited aggregation by ~46%. In the 
case of the Tau3RD aggregation assays, over 20% of the synthesized hits had a significant 
effect in reducing the aggregation of Tau3RD (up to ~36% compared to control), while control 
compound bb14 inhibited aggregation by ~84%. Lastly, in the case of the Tau4RDΔK280 
aggregation assays, over 35% of the synthesized hits had a significant effect in reducing the 
aggregation of Tau4RDΔK280 (up to ~54% compared to control), while reference compound 
bb14 inhibited aggregation by ~58%. In summary, the synthesized hits reduced fibril 
formation of the tested Tau constructs by different extents (Fig. 4). 6 compounds significantly 
reduced aggregation of Tau3RD and of Tau4RDΔK280, 5 compounds significantly reduced 
aggregation of hTau2N4Rwt and of Tau4RDΔK280, and 4 compounds significantly reduced 
aggregation of hTau2N4Rwt and of Tau3RD. Only 2 compounds had a significant effect in 
reducing the aggregation of all Tau constructs tested in vitro. 
A few of the compounds promoted a strong increase in the ThS-fluorescence signal, 
up to ~8-25 fold compared to the control. This increase does not reflect a higher extent of Tau 
aggregation (as ascertained by pelleting and SDS-PAGE), but rather an interference between 
the compound and ThS which changes the fluorescence properties (note that, depending on 
isoform and conditions, ~40-80% of the protein aggregates, so that any aggregation-
promoting compound could at best enhance the extent of aggregation by up to ~2.5-fold). 
Analogous non-linear increases in ThS fluorescence have been observed in other conditions, 
for example during Tau aggregation in presence of arachidonic acid near the critical micellar 
concentration[38; 39]. We therefore conclude that these compounds are not Tau aggregation 
promoters. 
Specific selected examples of compounds, ID220149, ID220218 and ID220255 (see 
Fig. 3B), which reduced Tau fibril formation in ThS aggregation assays are shown in Fig. 3A 
and Table 4, representing three distinct compound series from among the Tau binders 
identified in the HT-CM-SPR screen. The relative ThS fluorescence in the ThS aggregation 
assays was measured as degree of Tau fibril formation, which was already confirmed by other 
methods (filter- and pelleting assay [10]). For comparison, the Tau aggregation inhibitor bb14 
(from the rhodanine class of compounds described previously [40]) was tested as well as 
reference value. 
 
A majority of Tau binding compounds affect the aggregation of Tau4RDΔK280 in regulatable 
N2a cells 
Next, we tested the synthesized hits for their ability to inhibit Tau aggregation in an 
inducible N2a cell model, which expresses Tau construct Tau4RDΔK280. N2a cells with 
Tau4RDΔK280 aggregates were stained by ThS and visualized by fluorescence microscopy 
(Fig. 5A). This allows discrimination of cells with aggregated Tau from cells with soluble Tau 
(Fig. 5A, background) or cells without Tau expression (Fig. 5B, highlighted inset 
demonstrates the presence of cells). Fig. 5 (C1-C5) shows examples of the quantification of 
Tau aggregation in uninduced N2a cells (column C1), induced cells (column C2) and 60 µM 
compound treated cells (column C3 – C5) by FACS analysis. In parallel the cell viability was 
measured at the same compound concentrations by MTT assay. The extent of Tau4RDΔK280 
aggregation and cell viability in the compound-free control is normalized to 100% (results 
summarized in Table 4). Notably, at least two thirds of the hits had a substantial effect in 
reducing Tau4RDΔK280 aggregation. The most potent half dozen compounds were between 
70-84% compared to control, among which were compounds, ID220149, ID220218 and 
ID220255 shown in Fig. 3 and Table 4, representing three distinct compound series from 
among the Tau binders identified in the HT-CM-SPR screen. As a reference for aggregation 
in cells, the Tau aggregation inhibitor BSc3094 (from the phenylthiazolyl-hydrazide class 
[41]) was tested as well, which reduced aggregation of Tau4RDΔK280 by 93%. 
The rhodanine derivative bb14 showed in the cellular assays an increasing 
fluorescence staining of the whole cell population in the FITC channel when excitated at 495 
nm (Fig. S3C). Because of this phenomenon we used compound BSc3094 as reference for the 
cell experiments (FACS and MTT-assay) where this effect does not occur (Fig. S3D). None 
of the novel compounds showed such a fluorescence-shifting effect in the cellular system (for 
example see Fig. 5C3 – C5). 
 
Selected hit compounds inhibit Tau aggregation in a dose dependent manner in N2a cells 
inducible to over-express Tau4RDΔK280 
We selected three representative synthesized hits, ID220149, ID220218 and 
ID220255, due to their superior ability to reduce aggregation of the different constructs of Tau 
in vitro and in N2a cells and for their CNS drug-like physico-chemical properties, and tested 
them for their ability to inhibit Tau aggregation and cell viability in the inducible 
N2aTau4RDΔK280 cell line [37] at increasing concentrations (0, 5, 10, 30 and 60 µM). The 
aggregate load in the N2a cells was quantified via ThS+ cells counted by FACS and the cell 
viability was measured by MTT-assay (Fig. 6). 
An optimal aggregation inhibitor compound should have low cytotoxicity (high MTT 
value) over a wide concentration range, with a decrease in cell viability only at high 
concentrations. By contrast, the amount of ThS+ cells should decrease with increasing 
compound concentrations, indicating that the compound inhibits Tau aggregation effectively 
in a dose responsive manner. In this latter case the separation between the MTT- and ThS+ 
cell-curves should become maximal (Fig. 6A). 
Overall, all three hits tested in N2a cells showed a dose-dependent inhibition of 
Tau4RDΔK280 aggregation. Compound ID220149 (Fig. 6B) causes a moderate decrease in cell 
viability at higher concentrations tested but shows a relatively strong decrease in the amount 
of ThS+ cells at lower tested concentrations. Since the aim is to maximize cell viability and 
minimize the amount of ThS+ cells; one can best judge the quality of these parameters at the 
concentration of 30 µM. In this respect ID220149 showed the best dose-response effect on the 
N2a cells among the presented compounds. Treatment with ID220218 (Fig. 6C) illustrates a 
case where the curves of the MTT-value and ThS+ cells decrease in a parallel manner. This 
suggests that the reduction of ThS+ cells could be caused by the increasing cytotoxicity at 
higher compound concentrations. By contrast, ID220255 (Fig. 6D) shows a stable value of 
cell viability over the entire concentration range but a reduction of the amount of ThS+ cells 
only at high compound concentration. This could be explained by some metabolic instability 
of the compound or an insufficient ability to pass the cell membrane. 
 
Cell active Tau aggregation inhibitors do not compete with ThS for binding to Tau fibrils 
To examine possible optical interference by the compounds with the fluorescence of 
ThS (excitation and emission of ThS that is bound to aggregated Tau), we measured 
absorption scans in the range of 230 to 1000 nm (Fig. 7A). Almost no absorption by the hits 
was observed, especially at the wavelengths of 440 nm and 521 nm, which suggest that the 
compounds do not interfere with the fluorescence of ThS. 
It is plausible that some of our Tau binding compounds may bind to Tau fibrils. Thus, 
they could compete with ThS for binding to Tau fibrils, which could potentially lead to the 
dislocation of ThS from Tau aggregates, leading to a reduced fluorescence signal and 
therefore cause false-negative results. (Note that ThS bound to Tau fibrils containing beta 
structure leads to a change in its fluorescence emission spectrum when excited at 440 nm. The 
increase at 521 nm serves as an indicator of Tau aggregation.) To test this, we performed co-
staining experiments of Tau3RD fibrils with ThS and compounds ID220149, IS220218 and 
ID220255 at molar ratios of 1:1 and 1:10 (ThS:compound). If some of these compounds were 
able to displace ThS from the protein one would expect a reduced fluorescence signal 
compared with the control of ThS alone (Fig. 7B). However, compared with the compound-
untreated control (Fig. 7B, entry #1) there is no significant difference in the fluorescence 
signal when treating with ThS plus compound or with ThS alone. This indicates that the 
compounds are not able to displace ThS from Tau fibrils. 
 
Characterization of the self-aggregation ability of synthesized hits by DLS 
The mechanism of protein aggregation modulation by a compound may occur by the 
self-assembly of the compound into a multimer/oligomer particle and consequent interactions 
with monomeric or oligomeric forms of the aggregating protein [16; 17]. This is a probable 
mechanism of many compounds inhibiting amyloid formation for a variety of proteins [16]. 
To investigate this possibility, the oligomerization properties of all 70 synthesized hits were 
investigated by measuring the hydrodynamic radii of the compounds by dynamic light 
scattering (DLS) under similar sample conditions to those used in the aggregation assays 
(Table 4, column 10). These DLS experiments showed, for example, that compounds that 
inhibited Tau aggregation in the N2a cells in a dose dependent manner (ID220149, ID220218, 
ID220255) are soluble and do not form detectable compound aggregates in the assayed 
conditions. These results suggest that these synthesized hits function in the aggregation assays 
as monomers. 
 
 
Discussion  
 
We have pursued an SPR array screening approach to identify novel fragment and 
lead-like small molecules capable of binding hTau2N4Rwt and elucidated the ability of the 
binders to modulate the aggregation of Tau3RD and Tau4RDΔK280 in vitro and in N2a cells. 
Our experiments resulted in the identification of dozens of novel compounds that inhibit the 
aggregation of distinct Tau constructs in vitro and in cells. These results strongly provide 
initial support for our drug discovery approach to develop small molecules that can bind to 
Tau in its intrinsically disordered state, and protect it from aggregating.  
A prominent challenge is the identification of small molecule binders of intrinsically 
disordered proteins, because these proteins lack stable tertiary structure. Moreover, an 
additional complication is represented by the limited availability of high-throughput screening 
techniques with the ability to detect direct binding of small molecules to label-free and 
solution-free biomolecule receptors. In fact, there is no other high-throughput screening 
technique available yet, other than HT-CM-SPR, which has these capabilities and is capable 
of performing under near physiological conditions and concentrations of Tau. A further 
advantage of this optical label-free technique for our studies is its high sensitivity to detect 
weak intermolecular interactions. This results from the fact that high molecular weight protein 
analytes, such as hTau2N4Rwt, induce large changes in refractive index when binding to the 
immobilized compounds, and hence effectively increase the sensitivity and limit of detection 
of the method (Fig. 1B-D).  
Compounds identified in the HT-CM-SPR screen that interact with hTau2N4Rwt may 
be binding to distinct locations and regions of Tau. Further studies will be required to 
established whether those compounds that bind to the four-repeat region of Tau, which is 
responsible for formation of the core structure of Tau fibrils [42], are most likely to have a 
role in modulating Tau aggregation. Also, compounds that bind to other parts of Tau, where 
they may be involved in stabilizing transient tertiary interactions that support the overall 
"paperclip" structure of Tau [25], may also affect the aggregation propensity of Tau. 
Stabilization of the Tau paperclip structure could reduce misfolding of Tau, for example, by 
protecting the domain of the repeats from intermolecular interactions [25]. Likewise, these 
compounds may simply support the native disordered ensemble of Tau and protect it from 
misfolding. Therefore, the locations of the binding sites of the compounds can have a 
pronounced effect on Tau structural stability and misfolding. This idea is supported by the 
data that some binders reduced the aggregation of distinct constructs of Tau to different to 
different extent, while others did not show any observable effect. 
It was not clear whether the weak binding of the compounds to hTau2N4Rwt in the HT-
CM-SPR assay would have enough impact to interfere with the protein-protein interaction 
involved in the aggregation process. For example, a weak-binding compound may be 
displaced by another Tau monomer, by cofactors such as heparin or other polyanions. 
Nevertheless, the Tau binding hits were able to reduce fibril formation of Tau constructs to 
different extents. They reduced the fibril formation of Tau4RDΔK280 the most, then of Tau3RD 
and the least of hTau2N4Rwt. The full-length isoform hTau2N4Rwt (2N4R, 441 amino acid 
residues) is approximately 4 times larger than the 3-repeat construct Tau3RD (99 residues). 
Given that Tau is a largely unstructured protein, accessible to solvent along the whole chain, 
compounds could possibly bind to several sites along the chain. In this case, the compound 
concentration, which might affect Tau aggregation in the repeat domain, could be effectively 
diluted several-fold when comparing the repeat domain to full-length Tau. The aggregation of 
hTau2N4Rwt in vitro is very slow and has to be catalysed by heparin. Heparin binds to 
monomeric Tau, which likely neutralizes the charge in the basic repeat region of Tau [33] 
thereby inducing structural changes in the protein [43] that enhances a structural ensemble 
favoring nucleation [44]. The N- and C-terminal domains of hTau2N4Rwt slow down 
aggregation because they protect the four repeat region [25], so that it requires incubation 
times up to 10 days and 5-fold higher protein concentrations than that required for Tau3RD and 
Tau4RDΔK280 aggregation assays, in order to obtain sufficient fibrillization. Heparin cannot 
be reduced appreciably because this would lead to even longer aggregation times. Such long 
incubation times at 37°C may influence hit compound stability and activity in these assays. 
Aggregation assays with Tau3RD construct are much faster (12 h at 37°C) in the presence of 
heparin [32]. In both assays, hit compounds had a significant effect in reducing fibril 
formation or promoting more fibril formation, however the reducing effects were not as 
substantial as observed in Tau4RDΔK280 aggregation assays. We speculate that one of the 
reasons for the small aggregation modulation effects of the hits in the hTau2N4Rwt and Tau3RD 
assays is that heparin competes with hit compounds for binding to hTau2N4Rwt. NMR studies 
demonstrated that heparin can bind to monomeric full length Tau along its whole sequence 
with an affinity as high as low µM at some sites [43]. (The binding of negatively charged 
heparin to Tau may be non-specific and driven mostly by salt bridge formation.) Furthermore, 
these NMR experiments [43] and recent single molecule FRET measurements [44] showed 
that the interaction between heparin and Tau induces substantial structural changes throughout 
the protein, for example, β-strand structure in certain regions in the four repeat region and α-
helical structure in some regions outside of the four repeat region [43], while it releases long-
range intramolecular interactions and compacts the microtubule binding region. Such 
structural changes in Tau also likely limit the ability of hit compounds to interact with 
monomeric Tau.  
In case of the Tau construct Tau4RDΔK280, which contains one of the FTDP-17 
deletion mutations, the aggregation assay can be performed in the absence of heparin because 
of its high propensity to aggregate [38; 45]. These results allow one to exclude artificial 
perturbations to Tau structure due to heparin. Indeed, in this assay two thirds of our Tau 
binding compounds had a significant effect in modulating Tau4RDΔK280 aggregation and 
notably 35% of them had a substantial effect. As a result of the use of heparin and the 
different Tau constructs, it is not surprising that no correlation in the degree of aggregation 
reduction by the hits was observed, although several hit compounds had significant 
aggregation inhibition effect in all in vitro and cellular assays (Table 4).  
In N2a cells, the hit compounds, in general, had a more extensive ability to reduce 
fibril formation of Tau4RDΔK280, compared to in vitro experiments. One reason for this may 
be the fact that there is less Tau4RDΔK280 in the cells and thus less amount of compound is 
needed to have a functional effect. No significant correlation in the ability of hit compounds 
to reduce aggregation of Tau4RDΔK280 in N2a cells compared to in vitro was observed, 
however, several hit compounds had significant aggregation inhibition effect in both cellular 
and the in vitro assay (Table 4 and Fig. 4). We further confirmed our findings by 
demonstrating that the three selected compounds (Table 4) reduced the aggregation of 
Tau4RDΔK280 in Na2 cells in a dose dependent manner. These hit compounds are likely to act 
via single compound monomer species, because DLS experiments did not detect self-
aggregated compound species at the assayed conditions. The concentration of the compound 
that can modulate aggregation is likely to depend on the relative ratio of protein and 
compound, therefore, the necessary compound concentration for in vivo aggregation 
modulation is determined by the absolute level of soluble monomeric Tau in neurons, which 
may be as low as 20 nM [22]. The functional effect of our compounds in reducing Tau 
aggregation is comparable to other reported optimized aggregation inhibitors. For example, 
the rhodanine based inhibitor bb14 [40] was less than 2 times more potent in reducing 
Tau4RDΔK280 aggregation in vitro compared to our best hits, while the phenylthiazolyl-
hydrazide based inhibitor BSc3094 [41] was about 2-3 more effective in reducing aggregation 
in N2a cells compared to our best hits. Independently of their inhibitory capacity, the reported 
hit compounds (Fig. 3 and Table 4) are promising starting points for hit optimization efforts, 
because these compound have no reactive fragments and generally have drug-like 
physicochemical properties.  
The use of absorption and fluorescence assays to monitor different physiological effect 
of compounds on cellular system (e.g. MTT-Assay, LDH-Assay) could be restricted by the 
optical properties of the investigated compound (see e.g. absorption spectra of methylene blue 
and azur A in [46]). In these cases ThS is not usable as an indicator of overall aggregation and 
has to be replaced by other methods (e.g. quantitative electron microscopy [47], filter trap [12; 
48] or pelleting assays [10; 11]. However, the compounds used in the present work have no 
absorption in the region critical for ThS fluorescence and therefore do not interfere with the 
fluorescence-based methods. 
Overall, the results suggest that hit compounds exert their functional effect by binding 
to Tau. Hit compounds may reduce the likelihood of Tau self-interactions and may also affect 
monomer to oligomeric/aggregated Tau interactions and thereby reduce secondary nucleation 
and aggregate growth. Indeed, it has been suggested that the rate-limiting step in the 
fibrillization pathway of Tau may be dimer formation, and filament elongation happens by 
addition of Tau monomers to nascent filament ends [26]. We can not exclude the possibility 
that hit compounds may also have an affinity toward oligomeric Tau and exert a functional 
effect that way a case that requires further investigation. Moreover, further studies will be 
needed to establish whether the compounds that we have presented here bind specifically to 
Tau or also to other proteins. Our approach of targeting the initial step of the fibrillization 
pathway is aimed at finding compounds that reduce the generation of toxic Tau oligomers and 
protect against Tau toxicity. Such therapeutic approach should be able to slow down 
progression of the disease as well as provide preventative effect.  
Parallel to our own efforts reported in this study, fluorescently labeled monomeric 
Aβ40 was screened by Chen and co-workers [49] using small molecules immobilized on 
microarrays. This screen resulted in identifying small molecule binders to Aβ40, which were 
found to promote the aggregation of Aβ40 and reduced the toxicity of Aβ40 in PC12 cells. 
Although the study did not find Aβ40 aggregation inhibitors, it supports one of the 
conclusions of this study that the presented screening approach can be extended to other IDPs.  
 
  
Conclusion 
 
We applied a high-throughput chemical microarray surface plasmon resonance 
imaging screen (HT-CM-SPR) to identify small molecule binders to monomeric hTau2N4Rwt. 
We identfied a diverse set of novel fragment and lead-like small molecules capable of binding 
Tau, some of which had the ability to inhibit the aggregation of full length Tau, three-repeat 
Tau construct Tau3RD, and pro-aggregant mutant four-repeat Tau construct Tau4RDΔK280 in 
vitro and in N2a cells. The discovery of these small-molecule binders to Tau demonstrates 
that despite its heterogeneous conformational ensemble and a lack of stable tertiary structure, 
it can be a viable receptor of small drug-like molecules, a finding that may be valid for other 
IDPs and is in line with our and other recent reports[49; 50]. Some of the small-molecule 
binders to Tau exerted a functional effect by reducing the aggregation propensity of Tau 
(Table 4). Several of the identified novel aggregation inhibitors (Table 4) are drug-like small 
molecules that are suitable starting scaffolds for hit to lead optimization and for efficacy 
studies in relevant in vivo models of AD. Overall, these results support the potential and 
practical feasibility of the therapeutic strategy to target the early phases of the aggregation 
pathway of IDPs by a small molecule to reduce initial or secondary nucleation events, thereby 
eliminating the formation of potential toxic oligomers. Such a strategy for Tauophaties could 
be of therapeutic value in both disease modifying and preventive contexts. The presented drug 
discovery paradigm has general applicability because it can be applied to any IDPs linked to 
misfolding diseases such as AD, Parkinson’s Disease, FTDP and others.  
 
	    
  
 Figure/Table Legends 
 
Fig. (1). The HT-CM-SPR scheme. (A) The protein analyte is allowed to float over the array 
surface under controlled conditions to allow binding events to happen. SPR Imaging enables 
the detection of binding events: (B) Close-up of a grey scale picture obtained by CCD camera 
imaging of chemical microarray. (C) Grey scale analysis resulted in the parallel detection of 
9,216 SPR minima per microarray exhibiting a shift in the resonance wavelength upon protein 
binding to the immobilized compounds. (D) Generic example of a color coded visualization 
of one array experiment. 
 
Fig. (2). SPR Screening Results. Example of colour coded SPR signals obtained by chemical 
microarray screening of hTau2N4Rwt under optimized conditions against: (A) a fragment 
library of 3,000 fragments (out of 25,000 fragments present in the small molecule library 
screened) spotted in triplicates, and (B) a lead-like library combining (96x96 =9,216) motifs. 
Reproducibility of screening experiments for chemical microarray with (C) fragments and for 
(D) lead-like compounds immobilized. 
 
Fig. (3). (A) Thioflavin S fluorescence as indicator for the extent of Tau aggregation after 
incubation with compounds. Bar colors: Grey hTau2N4Rwt; red Tau3RD; green Tau4RDDK280; 
blue ThS+ N2a cells (expressing Tau4RDDK280 with aggregates); orange viability of N2a cells 
(MTT assay). Reference results are shown for earlier studies with different classes of 
compounds: in vitro studies with bb14 [40],, cellular studies with BSc3094 [41]. The in vitro 
ThS-signal of the soluble Tau protein was subtracted from all samples. (B) Examples of 
chemical structures of Tau binding compounds identified by HT-CM-SPR screen.  
 
Fig. (4). Graphical representation of the effect of hit compounds on the aggregation of 
different Tau constructs in vitro and in N2a cells. No significant correlation was observed in 
the ability of hit compounds to reduce aggregation of the different Tau constructs (A) in vitro 
and (B) Tau4RDΔK280 in N2a cells. Nevertheless, several hit compounds had significant 
aggregation inhibition effect in both cellular and the in vitro aggregation assays. 
 
Fig. (5).  N2a cells with Tau aggregates stained by Thioflavin S. Fluorescence microscopy 
shows a representative section of the N2a cell population after 4 days of Tau expression. Cells 
bearing higher Tau aggregates appear bright green (A) whereas cells with soluble or 
oligomeric Tau show only background staining (A, green background), similar to cells 
without any Tau expression (B). (C1 – C5) shows examples of cell distributions by FACS 
counting after 4 days of incubation, without Tau expression (C1, negative control), with Tau 
expression (C2, positive control), and with Tau expression in the presence of Tau-aggregation 
inhibitors ID220149 (C3), ID220218 (C4) and ID220255 (C5). The cell signals were plotted 
with regard to cell morphology (upper panels: FSC (forward scatter indicating the particle 
size) vs. SSC (side scatter indicating the particle granularity), and with regard to the amount 
of cells with Tau aggregates (lower panels: FSC vs. fluorescence intensity measured in the 
FITC channel). Cell debris would appear as small particles (small FSC values) with high 
density (high SSC values). Note that the green ThS+ cells are well separated from the cell 
debris population shown in black. The reduction of aggregate-bearing cells by the inhibitor is 
apparent from the lower panels. 
 
Fig. (6). Comparison of N2a cell viability (MTT assay) with the amount of ThS+ cells 
(FACS) at increasing compound concentrations. Promising compounds should show a 
relatively high stable cell viability value over a broad concentration range whereas the amount 
of ThS+ cells should drop already at low compound concentrations (A). By this criterion, 
compound ID220149 (B) is the best inhibitor in this series wereas ID220218 (C) and 
ID220255 (D) show less effectivity and drug-like performance. Note: The MTT value in the 
untreated sample (without compound) is defined as 100% cell viability. The amount of ThS+ 
cells in the Tau-induced control is normalized to 100%. 
 
Fig. (7). (A) Absorption properties of selected compounds. 200 µM of the compound (in PBS 
+ 2% DMSO) were sanned over a wavelength range of 230 to 1000 nm and plotted against 
the absorption value. (B) Staining of pre-formed Tau fibrils with Thioflavin S (ThS) in 
combination with selected compounds or with compound alone. The y-axis represents the 
amount of aggregated Tau protein monitored by ThS-fluorescence.  
 
 
Table 1. Summary of hit molecular scaffolds identified by the HT-CM-SPR of hTau2N4Rwt. 
 
Table 2. Molecular weight distribution of hits identified by the HT-CM-SPR of hTau2N4Rwt. 
 
Table 3. Ranges of selected physicochemical properties for the 118 hits identified by the HT-
CM-SPR of full length hTau2N4Rwt as well as for the 70 resynthesized compounds. 
 
Table 4. Summary of the effects of selected synthesized hits on Tau aggregation in vitro 
and in N2a cells. (Column 5 – 7) The relative ThS-fluorescence was used to indicate the 
degree of tau fibril formation after compound treatment. The fluorescence of the compound 
untreated control (“DMSO - Dox”) was normalized to 100% (note: 2% DMSO were added to 
the controls to ensure comparable conditions to the compound treated samples). (Column 8) 
The amount of ThS+ cells (cells with tau aggregates stained by ThS and quantified by FACS) 
in the induced compound-untreated sample (”DMSO + Dox”) was normalized to 100%. 
(Column 9) The cell viability (monitored by MTT-assay) of the uninduced compound-
untreated sample (entry #1, right column) was normalized to 100%. MTT-values reflect the 
viability of the N2a cells in the presence of the compounds without expression of tau protein. 
(Column 10) Concentrations at which synthesized hits were soluble and no compound 
aggregates were detected by DLS. 
 
Fig. (S1). HTau2N4Rwt stock preparation, used as starting material fort the screen, showing 
that the protein was monomeric. 10% SDS-PAGE of HTau2N4Rwt stock prepared in PBS 
buffer at pH 7.4 with 1 mM DTT at 1 mg/ml (22 µM) concentration. HTau2N4Rwt appears as a 
single band by Coomassie Blue staining. The purity of the protein is > 95%. 
 
Fig. (S2). Electron micrographs of Tau4RDΔK280 fibrils after 10 days of incubation. A and B 
– without compound; C – in the presence of anti-aggregation compound (10 µM Tau protein 
+ 60 µM bb14[34] after 12 hours incubation at 37 °C). 
 
Fig. (S3). Comparison of tau expressing N2a cells when treated with anti-aggregation 
compounds. N2a cells expressing the tau construct K18ΔK280 were incubated with the 
rhodanine derivative bb14 [34] and the phenyl-thiazolyl-hydrazide derivative BSc3094 [35] (15 
µM concentration in the medium) for 4 days and the amount of ThS-positive cells was 
analyzed by FACS. The induced cells without compounds shows an amount of ThS-positive 
cells (located in the “GFP+”-field) which decreases in the presence of BSc3094 (compare B 
and D). In the samples treated with bb14 we observed a general upward shift of the whole cell 
population in the FITC channel. This observation suggests an artificial fluorescence effect of 
this compound in our cellular system. Because of this we used only the BSc3094 compound 
as reference for our cellular assays (FACS and MTT). 
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Table 1. 
 
 
Series Series Eponym Number of hits 
Affinity in 
HT-CM-SPRa 
1 phenoxy-acetamides 10 weak 
2 benzimidazoles 6 weak 
3 sulfonamides 6 weak 
4 ureas 5 weak 
5 carboxylic acids 7 medium 
6 tetrazoles 3 weak 
7 triazines 9 medium 
8 mesyl-phenyl-oxo-butyramides 4 weak 
9 cyano-benzamides 4 weak 
10 piperidinyl-methylfuran-carboxamides 4 weak 
11 structurally unrelated fragments 19 weak 
12 structurally unrelated lead-like compounds 41 weak-medium 
 
aAverage relative affinity of immobilized hits to hTau2N4Rwt detected by SPR in the HT-CM-SPR 
	   	  
Table 2.  
 
 
Molecular Weigh Distribution Number of hits 
fragments < 275 Da 13 
275 Da < fragments < 300 Da 13 
300 Da < lead-like < 350 Da 37 
300 Da < lead-like < 400 Da 31 
400 Da < lead-like 24 
 
 
  
Table 3. 
 
 
 
118 linked  
array hits 
70 compounds 
resynthesized 
Min Mean Median Max Min Mean Median Max 
MW 209.2 350.8 344.9 539.6 223.2 346.8 344.4 528.5 
ClogP  -2.32 1.76 2.07 4.21 -0.87 1.69 1.89 4.21 
#ACCEPTORS 2 4.3 4 9 2 3.9 4 6 
#DONORS 1 2.9 3 8 1 2.6 3 6 
#ROTBONDS 2 6.1 6 12 2 5.6 6 11 
#RINGCOUNT 1 2.7 3 4 1 2.7 3 4 
HAC 15 24.9 25 38 16 24.8 25 38 
TPSA 35.6 95.7 89.8 200.9 35.6 87.5 81.3 157.9 
 
For immobilization to the chip surface all library compounds were tethered to the chip via a linker group R. In 
order to calculate the ClogP, H-bond acceptor count, H-bond donor count, the count of rotatable bonds and 
topological polar surface area for the 118 array hits, this R-group was virtually replaced by a carbon. For the 
calculation of the molecular weight (MW) and Heavy Atom Count (HAC) the R group was replaced by 
hydrogen. In case of the 70 resynthesized compounds the linker group R at the attachment point at the compound 
was synthetically replaced by other groups such as methyl groups, which are included in the calculation of all 
properties. The following software was used: Hivol for the calculation of the counts, Biobyte for the calculation 
of ClogP and Openbabel v. 2.3.1 for the calculation of total polar surface area (TPSA). 
 
  
 
Table 4.  
 
 
1 2 3 4 5 6 7 8 9 10 
Hit ID Hit Series MW 
Affinity 
HT-CM-
SPRa 
hTau2N4Rwtb Tau3RD c 
Tau4RD 
ΔK280d 
Tau4RD 
ΔK280 
N2a cellse 
viability 
N2a cells 
(MTT) 
solubility 
(µM) 
bb14[34]  452.0  54.3 ± 8.3 14.0 ± 0.1 42.0 ± 1.6    
BSc3094[35]  380.4     7.2 101.9 ± 3.8  
          
DMSO 
(- Dox)    100 ± 5.5 100 ± 13.0 100 ± 5.4 0.1 100 ± 1.3  
          
DMSO 
(+ Dox)       100   
          
ID220149 7 375.6 medium 105.8±13.6 83.6± 2.6 69.8 ± 4.3 29.6 74.1 ± 0.8 300.0 
ID220218 3 359.4 weak 97.4± 7.1 86.0± 4.7 77.1 ± 5.9 38.6 57.8 ± 3.0 300.0 
ID220255 12 406.4 weak 113.2 ± 4.4 107.9± 2.5 78.9 ± 5.4 25.0 86.6 ±6.5 150.0 
 
aRelative affinity of immobilized hits to hTau2N4Rwt detected by SPR in the HT-CM-SPR. 
Percentage of aggregated hTau2N4Rwtb, Tau3RD c and Tau4RDΔK280d detected by ThS fluorescence in the 
presence of hit compound compared to control (100%). 
 
	  
